Assembly Biosciences (ASMB) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Share on StockTwits

Assembly Biosciences (NASDAQ:ASMB) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.01) by $0.14, MarketWatch Earnings reports. Assembly Biosciences had a negative return on equity of 66.34% and a negative net margin of 457.20%. The firm had revenue of $4.29 million for the quarter, compared to analysts’ expectations of $3.21 million.

Shares of NASDAQ ASMB traded down $2.19 during mid-day trading on Friday, hitting $23.40. 193,657 shares of the stock traded hands, compared to its average volume of 168,602. Assembly Biosciences has a 52 week low of $20.61 and a 52 week high of $67.36. The firm has a market capitalization of $585.27 million, a PE ratio of -9.71 and a beta of 1.43.

In related news, VP Uri A. Lopatin sold 15,204 shares of Assembly Biosciences stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $40.09, for a total transaction of $609,528.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 18.20% of the company’s stock.

Several research firms have recently issued reports on ASMB. Robert W. Baird began coverage on Assembly Biosciences in a research note on Wednesday, August 8th. They set an “outperform” rating and a $74.00 target price on the stock. BidaskClub cut Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, July 13th. Chardan Capital reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Sunday, October 28th. Zacks Investment Research cut Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. Finally, B. Riley raised Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Monday, October 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $62.60.

ILLEGAL ACTIVITY WARNING: This article was first posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://macondaily.com/2018/11/10/assembly-biosciences-asmb-posts-quarterly-earnings-results-beats-estimates-by-0-14-eps.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Story: Stock Symbols Definition, Examples, Lookup

Earnings History for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply